Alpha 2.0
Login Register
» Authors » Zsolt Talloczy

Zsolt Talloczy

Explore the profile of Zsolt Talloczy including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 4982
Followers 0
Related Specialties
Cell Biology
Rheumatology
Microbiology
Top 10 Co-Authors
Beth Levine
Brian Porter
David Sulzer
Guomei Tang
Zhenyu Yue
James E Goldman
Pierre Maheux
Anastasia Lesogor
Atul Deodhar
Ana Maria Cuervo
Published In
Autophagy
Cell Host Microbe
Lancet Diabetes Endocrinol
Proc Natl Acad Sci U S A
Hum Mol Genet
Affiliations
Soon will be listed here.
Recent Articles
1.
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial
Wright R, Raal F, Koenig W, Landmesser U, Leiter L, Vikarunnessa S, et al.
Cardiovasc Res . 2024 May; 120(12):1400-1410. PMID: 38753448
Aims: Data describing the long-term efficacy and tolerability of inclisiran are limited. This was explored in ORION-8, an open-label extension of preceding Phase 2 and Phase 3 placebo-controlled and open-label...
2.
Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial
Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A, et al.
Circulation . 2023 Oct; 149(5):354-362. PMID: 37850379
Background: Homozygous familial hypercholesterolemia is a genetic disease characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) and a high risk of premature cardiovascular events. The proof-of-concept study ORION-2...
3.
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
Ray K, Troquay R, Visseren F, Leiter L, Wright R, Vikarunnessa S, et al.
Lancet Diabetes Endocrinol . 2023 Jan; 11(2):109-119. PMID: 36620965
Introduction: Whether long-term treatment with the twice-yearly, siRNA therapeutic inclisiran, which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9), results in sustained reductions in LDL cholesterol with an...
4.
Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials
Dougados M, Kiltz U, Kivitz A, Pavelka K, Rohrer S, McCreddin S, et al.
Rheumatol Int . 2021 Nov; 42(2):205-213. PMID: 34773130
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce pain and inflammation, and are considered the cornerstone of pharmacological intervention in patients with radiographic axial spondyloarthritis (r-axSpA); however, the long-term...
5.
Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1
Tseng J, Cheng-Chung Wei J, Deodhar A, Martin R, Porter B, McCreddin S, et al.
Front Immunol . 2020 Dec; 11:561748. PMID: 33324394
Objectives: To present the long-term (4-year) efficacy and safety of secukinumab in Taiwanese patients with active AS in the MEASURE 1 extension study. Methods: This analysis reports data from Taiwanese...
6.
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, et al.
RMD Open . 2019 Oct; 5(2):e001005. PMID: 31565244
Objective: This study aimed to report end-of-study results on efficacy and safety of secukinumab 150 mg through 5 years in patients with ankylosing spondylitis (AS; MEASURE 1 extension trial (NCT01863732))....
7.
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
Braun J, Baraliakos X, Deodhar A, Poddubnyy D, Emery P, Delicha E, et al.
Rheumatology (Oxford) . 2018 Dec; 58(5):859-868. PMID: 30590813
Objective: To evaluate the effect of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, on efficacy, imaging outcomes, and safety through 4 years (208 weeks) in patients with ankylosing spondylitis. Methods:...
8.
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study
Kivitz A, Wagner U, Dokoupilova E, Supronik J, Martin R, Talloczy Z, et al.
Rheumatol Ther . 2018 Aug; 5(2):447-462. PMID: 30121827
Introduction: To evaluate the efficacy and safety of secukinumab 150 mg, with or without a loading regimen, using a self-administered prefilled syringe in patients with ankylosing spondylitis (AS) over 104 ...
9.
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial
Baraliakos X, Kivitz A, Deodhar A, Braun J, Wei J, Delicha E, et al.
Clin Exp Rheumatol . 2017 May; 36(1):50-55. PMID: 28516874
Objectives: Secukinumab, a fully human anti-IL-17A monoclonal antibody, provided rapid and sustained improvements in signs and symptoms of ankylosing spondylitis (AS) over 2 years in the Phase 3 MEASURE 1...
10.
Adaptive autophagy in Alexander disease-affected astrocytes
Tang G, Yue Z, Talloczy Z, Goldman J
Autophagy . 2017 Feb; 4(5):701-703. PMID: 28186854
The ubiquitin-proteasome and autophagy-lysosomal pathways are the two main routes of protein and organelle clearance in eukaryotic cells. The proteasome system is responsible for unfolded, short-lived proteins, which precludes the...